Investment Thesis
Microbot Medical is an early-stage medical device company with minimal revenue ($105K quarterly) and unsustainable cash burn (-$5.2M quarterly FCF), leaving only 3.7M in remaining cash—less than one quarter of runway. While the balance sheet shows $74.1M in equity with minimal debt, the 1.9% gross margin and -$4.3M operating losses demonstrate fundamental unprofitability with no clear near-term path to sustainability.
Strengths
- Strong balance sheet with $74.1M stockholders equity and 0.03x debt-to-equity ratio
- Excellent liquidity position (22.59x current ratio) provides flexibility for immediate needs
- 100% year-over-year revenue growth demonstrates market demand and commercialization progress
- Low leverage provides capital cushion to execute business plan without imminent default risk
Risks
- Critical cash runway of less than one quarter given -$5.2M quarterly free cash flow and $3.7M cash balance
- Structural unprofitability with 1.9% gross margin and -$4.1B operating margin relative to revenue
- Minimal quarterly revenue of $105K insufficient to support $78.1M asset base and ongoing operations
- Operating cash flow negative at -$5.1M quarterly indicating business model is not self-sustaining
- Dilution risk from required capital raises or debt financing to extend operational runway
Key Metrics to Watch
- Quarterly revenue absolute levels and growth rate toward breakeven sustainability
- Gross margin expansion trajectory as manufacturing scales and product mix improves
- Operating cash flow inflection point toward positive cash generation
- Months of cash runway remaining and timing of next capital raise requirement
- Customer acquisition velocity and average selling prices in surgical robotics market
Financial Metrics
Revenue
105.0K
Net Income
-3.7M
EPS (Diluted)
$-0.05
Free Cash Flow
-5.2M
Total Assets
78.1M
Cash
3.7M
Profitability Ratios
Gross Margin
1.9%
Operating Margin
-4,114.3%
Net Margin
-3,496.2%
ROE
-5.0%
ROA
-4.7%
FCF Margin
-4,915.2%
Balance Sheet & Liquidity
Current Ratio
22.59x
Quick Ratio
21.93x
Debt/Equity
0.03x
Debt/Assets
5.1%
Interest Coverage
-18.23x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:47:37.995468 |
Data as of: 2026-03-31 |
Powered by Claude AI